propafenone has been researched along with Scleroderma, Systemic in 1 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
Scleroderma, Systemic: A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, BE | 1 |
| Jiang, X | 1 |
| Zhang, Q | 1 |
| Liang, Q | 1 |
| Qiu, ZL | 1 |
| Sun, XB | 1 |
| Yang, JJ | 1 |
| Chen, S | 1 |
| Yi, C | 1 |
| Chai, X | 1 |
| Liu, M | 1 |
| Yu, LF | 1 |
| Lu, W | 1 |
| Zhang, HK | 1 |
1 other study available for propafenone and Scleroderma, Systemic
| Article | Year |
|---|---|
From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis.
Topics: Designer Drugs; Drug Discovery; Humans; Receptor, Cannabinoid, CB2; Scleroderma, Systemic; Structure | 2021 |